We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam (ALNY) Gets EU Nod for Oxlumo to Treat Renal Disease
Read MoreHide Full Article
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that the European Commission (EC) has granted marketing authorization for Oxlumo (lumasiran), an RNAi therapeutic, for the treatment of primary hyperoxaluria type 1 (PH1) in all age groups.The ultra-rare disease causes a progressive decline in kidney function and can lead to end-stage renal disease.
Oxlumo is the first therapeutic approved for the treatment of PH1 and the only therapy proven to lower harmful oxalate levels that drive the progression of the PH1 disease.
Shares of Alnylam have gained 7.5% year to date against the industry’s decline of 1.7%.
The approval is supported by the efficacy and safety findings of Oxlumo in PH1 patients, including data from both ILLUMINATE-A and ILLUMINATE-B phase III studies. Key primary and secondary endpoints included the reduction of urinary and plasma oxalate and the proportion of patients achieving normalization or near-normalization of urinary oxalate in response to Oxlumo compared to placebo. This approval in the European Union follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in October 2020.
Oxlumo also enjoys the Priority Medicines (PRIME) designation by the EMA and the Orphan Drug designation in the European Union. Alnylam filed a new drug application (NDA) with the FDA. The FDA has granted a Priority Review to the NDA and set an action date of Dec 3, 2020.
Meanwhile, the company is also evaluating several other candidates. A few significant ones include vutrisiran and inclisiran. The company and partner Novartis’ (NVS - Free Report) inclisiranis under review in the United States and Europe for treating heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease.
Alnylam has a collaboration with Regeneron Pharmaceuticals (REGN - Free Report) to discover, develop and commercialize new RNAi therapeutics for a broad range of diseases by addressing disease targets expressed in the liver, eye and central nervous system.
Alimera’s loss per share estimates have narrowed from $1.31 to 96 cents for 2020 over the past 60 days. Shares of the company have decreased 37.3% year to date.
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Alnylam (ALNY) Gets EU Nod for Oxlumo to Treat Renal Disease
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that the European Commission (EC) has granted marketing authorization for Oxlumo (lumasiran), an RNAi therapeutic, for the treatment of primary hyperoxaluria type 1 (PH1) in all age groups.The ultra-rare disease causes a progressive decline in kidney function and can lead to end-stage renal disease.
Oxlumo is the first therapeutic approved for the treatment of PH1 and the only therapy proven to lower harmful oxalate levels that drive the progression of the PH1 disease.
Shares of Alnylam have gained 7.5% year to date against the industry’s decline of 1.7%.
The approval is supported by the efficacy and safety findings of Oxlumo in PH1 patients, including data from both ILLUMINATE-A and ILLUMINATE-B phase III studies. Key primary and secondary endpoints included the reduction of urinary and plasma oxalate and the proportion of patients achieving normalization or near-normalization of urinary oxalate in response to Oxlumo compared to placebo. This approval in the European Union follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in October 2020.
Oxlumo also enjoys the Priority Medicines (PRIME) designation by the EMA and the Orphan Drug designation in the European Union. Alnylam filed a new drug application (NDA) with the FDA. The FDA has granted a Priority Review to the NDA and set an action date of Dec 3, 2020.
Meanwhile, the company is also evaluating several other candidates. A few significant ones include vutrisiran and inclisiran. The company and partner Novartis’ (NVS - Free Report) inclisiranis under review in the United States and Europe for treating heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease.
Alnylam has a collaboration with Regeneron Pharmaceuticals (REGN - Free Report) to discover, develop and commercialize new RNAi therapeutics for a broad range of diseases by addressing disease targets expressed in the liver, eye and central nervous system.
Zacks Rank and Stock to Consider
Alnylam currently carries a Zacks Rank #4 (Sell).
A better-ranked stock in the healthcare sector includes Alimera Sciences Inc. (ALIM - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Alimera’s loss per share estimates have narrowed from $1.31 to 96 cents for 2020 over the past 60 days. Shares of the company have decreased 37.3% year to date.
Alnylam Pharmaceuticals, Inc. Price
Alnylam Pharmaceuticals, Inc. price | Alnylam Pharmaceuticals, Inc. Quote
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>